NCT05261295

Brief Summary

The main purpose of the study is to compare the effectiveness of PEEP application in terms of perioperative oxygenation level in the use of classical LMA and i-gel, which is often preferred. The secondary aim is to compare parameters such as gastric insufflation and the rate of postoperative pulmonary complication development in the case of PEEP with two supraglottic airway devices.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
128

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 11, 2022

Completed
18 days until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 2, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2022

Completed
Last Updated

March 2, 2022

Status Verified

February 1, 2022

Enrollment Period

3 months

First QC Date

February 11, 2022

Last Update Submit

February 25, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • LUS score preop

    Loss of ventilation will be evaluated by calculating the LUS score. Each region will be scored according to the LUS model as follows: Presence of lung deviation with lines or less than two isolated B-lines is scored as 0; 1 point in the presence of more than one well-defined B line; presence of more than one combined B line, 2 points; and when a tissue pattern characterized by dynamic air bronchograms (lung consolidation) is presented, the score is 3. The worst ultrasound pattern observed in each region will be recorded and used to calculate the sum of the scores.

    Baseline

  • LUS score postoperative

    Loss of ventilation will be evaluated by calculating the LUS score. Each region will be scored according to the LUS model as follows: Presence of lung deviation with lines or less than two isolated B-lines is scored as 0; 1 point in the presence of more than one well-defined B line; presence of more than one combined B line, 2 points; and when a tissue pattern characterized by dynamic air bronchograms (lung consolidation) is presented, the score is 3. The worst ultrasound pattern observed in each region will be recorded and used to calculate the sum of the scores.

    postoperative 1.hour

Study Arms (2)

Classical LMA

Patients who received general anesthesia with classical LMA

Diagnostic Test: PEEPDiagnostic Test: ZEEP

i-Gel

Patients who received general anesthesia with i-Gel

Diagnostic Test: PEEPDiagnostic Test: ZEEP

Interventions

PEEPDIAGNOSTIC_TEST

PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.

Classical LMAi-Gel
ZEEPDIAGNOSTIC_TEST

PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.

Classical LMAi-Gel

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who will undergo transurethral resection of the bladder and prostate taken in the lithotomy position, ureter and kidney stone operations with ureteroscopy

You may qualify if:

  • ASA I-III
  • Patients who will undergo transurethral resection of the bladder and prostate taken in the lithotomy position, ureter and kidney stone operations with ureteroscopy

You may not qualify if:

  • Heart failure (ejection fraction \< 40%),
  • unstable hemodynamic conditions
  • Having neck or upper respiratory tract pathology,
  • have an increased risk of aspiration (gastroesophageal reflux disease, full stomach, acidity),
  • obesity (body mass index≥30 kg m-2)
  • Patients with poor tooth structure will also be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • canan ün, MD

    ankara ch bilkent

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ahmet Demirörs, MD

CONTACT

canan ün, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

February 11, 2022

First Posted

March 2, 2022

Study Start

March 1, 2022

Primary Completion

June 1, 2022

Study Completion

July 1, 2022

Last Updated

March 2, 2022

Record last verified: 2022-02